IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.666
EU - Europa 2.266
AS - Asia 933
AF - Africa 23
SA - Sud America 8
OC - Oceania 7
Totale 10.903
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.651
FI - Finlandia 734
IE - Irlanda 502
CN - Cina 387
SG - Singapore 358
FR - Francia 269
DE - Germania 241
NL - Olanda 169
IN - India 148
GB - Regno Unito 99
IT - Italia 67
SE - Svezia 64
BE - Belgio 51
RU - Federazione Russa 20
NG - Nigeria 17
CZ - Repubblica Ceca 13
CA - Canada 8
JP - Giappone 8
HK - Hong Kong 7
PL - Polonia 6
AU - Australia 5
BR - Brasile 5
EG - Egitto 5
ES - Italia 5
CH - Svizzera 4
DK - Danimarca 4
IL - Israele 4
PA - Panama 4
RO - Romania 4
TW - Taiwan 4
VN - Vietnam 4
LU - Lussemburgo 3
MX - Messico 3
TR - Turchia 3
BG - Bulgaria 2
ID - Indonesia 2
IR - Iran 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
BN - Brunei Darussalam 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
PE - Perù 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 10.903
Salva come PNG Salva come JPEG
Città #
Chandler 2.263
Helsinki 733
New York 531
Dublin 502
Lawrence 460
Princeton 460
Boardman 443
Ashburn 426
Shanghai 274
Paris 266
Singapore 258
Amsterdam 159
Los Angeles 157
Pune 141
London 91
Seattle 60
Brussels 51
Santa Clara 49
Wilmington 37
Frankfurt am Main 32
Phoenix 30
Munich 22
Berlin 21
Milan 20
Moscow 18
Benin City 16
Falkenstein 15
San Mateo 14
Borås 12
Clifton 12
Guangzhou 10
Hanover 10
Brno 9
Ann Arbor 8
Tokyo 7
Washington 7
Leawood 6
Cairo 5
Chicago 5
Fairfield 5
Trieste 5
Warsaw 5
Zhengzhou 5
Beijing 4
Boston 4
Buffalo 4
Copenhagen 4
Nanning 4
Olomouc 4
Padova 4
Stockholm 4
São Paulo 4
Woodbridge 4
Zurich 4
Desio 3
Hanoi 3
Mexico City 3
Newark 3
Nuremberg 3
Rockville 3
Rome 3
San Francisco 3
Wuhan 3
Barnaul 2
Borgomasino 2
Champaign 2
Ferrara di Monte Baldo 2
Gunzenhausen 2
Hackensack 2
Hangzhou 2
Hyderabad 2
Jakarta 2
Jiangmen 2
Langfang 2
Lucknow 2
Luxembourg 2
Pioltello 2
Rio Vista 2
Sofia 2
Taipei 2
Taiyuan 2
Tel Aviv 2
Toronto 2
Treviglio 2
Trezzo sull'Adda 2
Veghel 2
Volendam 2
Ypsilanti 2
Ahmedabad 1
Alexandria 1
Algiers 1
Anaheim 1
Ankara 1
Athens 1
Auckland 1
Bandar Seri Begawan 1
Birmingham 1
Bogotá 1
Bollebygd 1
Bucharest 1
Totale 7.793
Salva come PNG Salva come JPEG
Nome #
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 59
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 59
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 58
Mesothelioma. From research to clinical practice 49
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 49
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 48
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 46
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 45
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 44
How Medicines are Born. The Imperfect Science of Drugs 43
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 42
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 41
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 41
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 40
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 39
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 39
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 39
Vinca alkaloids, taxanes and podophyllotoxins 39
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 38
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 37
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 37
Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles 37
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 37
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 37
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 36
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 36
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 36
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 36
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 36
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 36
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas 36
Dalla biologia alle terapie mirate 36
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 36
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 36
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 36
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 35
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 35
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study 35
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 35
Drug development (including phase I trials) 35
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 35
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 35
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 35
RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN 35
SAFETY PROFILE AND TOLERABILITY OF 'TRABECTEDIN AND INDOLE-3-CARBINOL COMBINATION IN REFRACTORY ADVANCED BREAST CANCER. PRELIMINARY RESULTS OF PHASE 1 CLINICAL STUDY 35
Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer 35
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 34
The potential impact of marine compounds in the era of targeting therapies 34
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer 34
Binding of imatinib by alpha(1)-acid glycoprotein 34
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 34
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 34
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 34
AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER 34
HMGA1 is a new biomarker of liposarcoma progression 34
Modulation of gene transcription by natural products - A viable anticancer strategy 34
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels 34
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 33
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 33
Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations 33
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 33
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 33
MIRNA LANDSCAPE IN STAGE I EPITHELIAL OVARIAN CANCER DEFINES THE HISTOTYPE SPECIFICITIES 33
Genetic Instability Influences Drug Response in Cancer Cells 32
microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition 32
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 32
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 32
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel 32
Roots of clinical resistance to STI-571 cancer therapy 32
Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours 32
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 32
Characterization of a protein recognizing minor groove binders-damaged DNA 32
Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models 32
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin 32
Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer.: Preliminary results 32
A FILTER INCUBATION METHOD FOR THE DETERMINATION OF POTENTIALLY CROSSLINKABLE SITES IN DNA IN MAMMALIAN-CELLS 32
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 32
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 32
DNA Damage Response and Immune Defense 32
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 31
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 31
Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth 31
Role of homologous recombination in trabectedin-induced DNA damage 31
L-asparagine-depletion: Another opinion - Response 31
Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma 31
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 31
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 31
Trabectedin therapy for sarcomas 31
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin 31
MIRNA181A-5P EXPRESSION AS A BIOMARKER OF TGFB PATHWAY ACTIVATION ASSOCIATED WITH ONCOLOGIC OUTCOME AND TUMOR DIFFUSION IN HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER 31
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 31
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 31
Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231 31
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 30
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice 30
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 30
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging 30
HIGH-DOSE MEDROXYPROGESTERONE ACETATE (MPA) IN ADVANCED EPITHELIAL OVARIAN-CANCER RESISTANT TO 1ST-LINE OR 2ND-LINE CHEMOTHERAPY 30
A novel taxane active against an orthotopically growing human glioma xenograft 30
Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors 30
Totale 3.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.375
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/202164 0 0 1 0 0 22 9 7 13 5 0 7
2021/2022244 2 4 0 7 1 0 0 7 19 5 67 132
2022/20236.451 1.028 151 587 747 428 614 5 689 1.147 573 412 70
2023/20243.809 333 309 938 283 106 679 113 195 39 176 365 273
2024/2025358 120 16 21 98 103 0 0 0 0 0 0 0
Totale 10.927